The term “nootropic” was coined by Romanian psychologist and chemist Corneliu Giurgea in 1972, who defined it as a compound that enhances learning and memory, protects the brain against physical or chemical injury, facilitates interhemispheric transfer of information, and has low toxicity with minimal side effects.
Since Giurgea’s original definition, the term has expanded to encompass a broad range of compounds that interact with neurological systems — neurotransmitters, neurotrophin signaling, dopaminergic and cholinergic pathways, mitochondrial function, and neuroimmune pathways — in ways that influence cognitive processes. This guide covers the science of nootropic research compounds, the major mechanisms under study, and the specific compounds in Chemyo Sarms’ research library. All information is presented strictly for educational and research reference purposes.
What Are Nootropics?
In the research context, “nootropics” broadly refers to compounds studied for their effects on cognitive function — including memory consolidation, learning acquisition, attention, processing speed, and neuroprotection. The category is heterogeneous: it includes peptides, small molecules, and synthetic compounds spanning multiple pharmacological classes.
Unlike SARMs (which target a single receptor class — androgen receptors), nootropic compounds work through diverse and often multi-target mechanisms. Some act primarily on neurotransmitter systems (glutamatergic, dopaminergic, cholinergic). Others affect neurotrophin expression, mitochondrial efficiency, or inflammatory signaling in neural tissue. Importantly, nootropic compounds do not produce hormonal suppression — they do not act on the hypothalamic-pituitary-gonadal axis. Their mechanisms are neurological rather than endocrine. See our Complete Guide to SARMs for context on the endocrine research compound space.
Classification: How Nootropics Are Categorized
Racetams and analogues: The original class of synthetic nootropics following Giurgea’s work on piracetam. These compounds interact primarily with AMPA-type glutamate receptors, enhancing receptor sensitivity and modulating acetylcholine release in cortical regions. Noopept is closely related pharmacologically and is often studied alongside this class.
Dopaminergic compounds: Compounds that modulate dopamine synthesis, release, reuptake, or receptor activity. Dopamine is central to motivation, working memory, executive function, and learning reinforcement. Bromantane has documented dopaminergic activity and represents this class in our research compound library.
Metabolic and mitochondrial agents: Compounds that improve neuronal energy metabolism, reduce oxidative stress in neural tissue, or support mitochondrial function. 5-AMINO-1MQ, an NNMT inhibitor, represents this emerging category.
Noopept (GVS-111)
Noopept — scientific name omberacetam, developmental code GVS-111 — is a synthetic dipeptide nootropic developed in Russia in the 1990s. It is structurally derived from the endogenous neuropeptide cycloprolylglycine (CPG), and its pharmacological activity is thought to be mediated in part through conversion to cycloprolylglycine following administration.
Mechanism of action: Noopept’s primary studied mechanisms include modulation of AMPA receptors, effects on acetylcholine neurotransmission in frontal cortical regions, and upregulation of NGF (Nerve Growth Factor) and BDNF (Brain-Derived Neurotrophic Factor) gene expression in preclinical models. The BDNF upregulation finding has attracted significant research interest, as BDNF plays a central role in synaptic plasticity, long-term potentiation, and neurogenesis.
Preclinical findings: Russian and international preclinical studies have examined Noopept’s effects on memory acquisition and retention in rodent models using Morris water maze and passive avoidance paradigms. Studies have also examined its potential neuroprotective properties in models of excitotoxic injury and cognitive impairment.
Bioavailability: Noopept is notable for its high oral bioavailability and blood-brain barrier permeability relative to its molecular weight. Its effective doses in rodent studies have been substantially lower than those of classical racetams like piracetam. It has a relatively short half-life in rodent models (typically under 2 hours), with rapid metabolism following oral administration.
→ View Noopept research compound
Bromantane (Ladasten)
Bromantane (INN: Ladasten) is an actoprotector and atypical psychostimulant originally developed in the Soviet Union. It has been in clinical use in Russia since 1996, registered as Ladasten for treatment of asthenic conditions — making it one of the more extensively documented compounds in this category.
Mechanism of action: Bromantane’s primary documented action is stimulation of dopamine biosynthesis — specifically through upregulation of tyrosine hydroxylase (TH) and DOPA decarboxylase (DDC), the rate-limiting enzymes in dopamine synthesis. It also affects serotonin synthesis and has documented GABA-potentiating activity at higher doses. This biosynthetic mechanism is pharmacologically distinct from dopamine reuptake inhibitors and is a primary driver of research interest, as it suggests a different risk profile relative to traditional stimulants.
Actoprotector classification: Bromantane belongs to a Soviet/Russian pharmacological category called “actoprotectors” — compounds that increase physical and mental performance under stress conditions without the arousal or tolerance patterns associated with classical stimulants. Actoprotector research remains an underexplored area in Western pharmacology, making Bromantane of particular interest to researchers studying stress resilience and performance-oriented neuropharmacology.
Immunomodulatory properties: A secondary area of research interest involves Bromantane’s reported immunostimulating effects. Published studies have examined effects on immunological parameters in animal models under stress conditions.
→ View Bromantane research compound
5-AMINO-1MQ
5-AMINO-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of NNMT — Nicotinamide N-methyltransferase — an enzyme expressed in adipose tissue, liver, and brain that regulates NAD+ metabolism and one-carbon metabolism pathways. It represents one of the newer mechanistic categories in cognitive and metabolic research compound science.
Why NNMT Matters: NNMT catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide and S-adenosylhomocysteine. This reaction depletes NAD+ precursors (by consuming nicotinamide before it can be recycled into NAD+) and consumes SAM, reducing the pool of methyl groups available for epigenetic methylation of DNA and histones.
NAD+ and cognitive research: NAD+ is a coenzyme central to cellular energy metabolism and a substrate for sirtuins — NAD+-dependent deacetylases involved in mitochondrial function, DNA repair, and longevity biology. Reduced NAD+ levels are associated in the aging literature with mitochondrial dysfunction and cognitive decline. Research into NNMT inhibitors like 5-AMINO-1MQ is driven partly by interest in raising intracellular NAD+ through upstream pathway modulation.
Preclinical research: Published studies on 5-AMINO-1MQ and related NNMT inhibitors have examined metabolic outcomes in diet-induced obesity models, including effects on adipose tissue and body composition. The cognitive research angle — investigating effects on neuronal NAD+ metabolism and mitochondrial function in neural tissue — represents an emerging area with published early-stage data.
→ View 5-AMINO-1MQ research compound
Comparing the Mechanisms
| Compound | Primary Mechanism | Primary Research Area |
|---|---|---|
| Noopept | AMPA modulation, BDNF/NGF upregulation | Memory, neuroprotection |
| Bromantane | Dopamine biosynthesis stimulation | Cognitive performance, stress resilience |
| 5-AMINO-1MQ | NNMT inhibition → NAD+ elevation | Metabolic/mitochondrial, neuroprotection |
These three compounds work through entirely distinct pathways, making them useful as research tools for studying different aspects of cognitive neuroscience and neurometabolism.
Sourcing Nootropic Research Compounds
Chemyo Sarms supplies Noopept, Bromantane, and 5-AMINO-1MQ as research-grade compounds with third-party COA documentation for each batch.
Frequently Asked Questions
What is the difference between a nootropic and a stimulant?
Stimulants primarily work through catecholamine reuptake inhibition to produce arousal and increased energy. Nootropics target a broader range of mechanisms including neurotrophins, AMPA receptors, and metabolic pathways, often without the pronounced arousal or cardiovascular activation of classical stimulants. Bromantane’s biosynthetic mechanism (rather than reuptake inhibition) is a specific example of this distinction.
Do nootropic research compounds suppress testosterone?
Noopept, Bromantane, and 5-AMINO-1MQ do not act on androgen receptors or the HPG axis and are not associated with testosterone suppression in the literature. This distinguishes them from SARMs, which typically produce HPG axis suppression as a consequence of androgen receptor agonism.
What is BDNF and why does it matter for cognitive research?
BDNF (Brain-Derived Neurotrophic Factor) is a neurotrophin that supports the survival, growth, and differentiation of neurons. It plays a critical role in long-term potentiation — the cellular basis of learning and memory — and is a biomarker studied extensively in research on cognitive aging, depression, and neuroprotection. Compounds like Noopept that show BDNF-upregulating activity in preclinical models are of interest because of BDNF’s established role in synaptic plasticity.
What is an actoprotector?
An actoprotector is a pharmacological category from Soviet/Russian research referring to compounds that increase physical and mental performance under extreme or stressful conditions without significant stimulant effects or tolerance. Bromantane is the most internationally recognized compound in this class. Western pharmacology has limited direct equivalents, which is part of why Bromantane is of research interest outside Russia.
Are any of these compounds approved for human use?
Bromantane (as Ladasten) is approved and prescribed in Russia for asthenic conditions. Noopept is available as a supplement in some countries. 5-AMINO-1MQ has no current regulatory approval anywhere. In the United States, none of these compounds is FDA-approved for therapeutic use, and they are sold strictly as research compounds.
All compounds described on this page are sold strictly for research purposes. They are not intended for human consumption. For educational reference only.